Cargando…

The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides

Known γ-secretase inhibitors or modulators display an undesirable pharmacokinetic profile and toxicity and have therefore not been successful in clinical trials for Alzheimer’s disease (AD). So far, no compounds from natural products have been identified as direct inhibitors of γ-secretase. To searc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Xiling, Yu, Jing, Niu, Qi, Liu, Jianhua, Fraering, Patrick C., Wu, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644980/ https://www.ncbi.nlm.nih.gov/pubmed/26567970 http://dx.doi.org/10.1038/srep16541

Ejemplares similares

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
por: Yang, Liyan, et al.
Publicado: (2021)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
por: Wu, Wenxue, et al.
Publicado: (2023)

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
por: Amen, Triana, et al.
Publicado: (2016)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimer’s disease
por: Gerber, Hermeto, et al.
Publicado: (2019)

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Natural Products Targeting Amyloid Beta in Alzheimer’s Disease
por: Lee, Joo-Hee, et al.
Publicado: (2021)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals
por: Mousavi Maleki, Masoumeh Sadat, et al.
Publicado: (2022)

Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease β-amyloid production
por: Rezai-Zadeh, Kavon, et al.
Publicado: (2009)

New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels
por: Schultz-Knudsen, Katrine, et al.
Publicado: (2020)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
por: Jie, Caitlin V. M. L., et al.
Publicado: (2021)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Data visualization explorer: A tool for participant representation in pivotal trials of FDA-approved medicinal products
por: Carmeli, Ariel B., et al.
Publicado: (2023)

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

A Robust and Efficient Production and Purification Procedure of Recombinant Alzheimers Disease Methionine-Modified Amyloid-β Peptides
por: Hoarau, Marie, et al.
Publicado: (2016)

Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid-β Peptide Associated with Alzheimer’s Disease Development
por: Urban, Anatoly S., et al.
Publicado: (2021)

Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update
por: Parrish, Richard H., et al.
Publicado: (2022)

The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus
por: Yeo, Won-Sik, et al.
Publicado: (2018)

β-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
por: Sun, Xiaojuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fnnnsst5nhrjhv24hfmj64maha